In this patient, lung adenocarcinoma remained progression-free for two years and five months with CBDCA-PEM plus ravulizumab, well beyond the approximately 5.5 month median PFS reported for this regimen in EGFR-TKI-resistant NSCLC [3]. This evidence concerns the gene EGFR and lung adenocarcinoma.